Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease

Table 1 Sequence of primers employed for quantitative real-time polymerase chain reaction

mRNA	Forward (5'-, -3')	Reverse (5'-, -3')
Mouse
Caspase-1	CACAGCTCTGGAGATGGTGA	GGTCCCACATATTCCCTCC
IL-1β	GCTGCTTCCAAACCTTTGAC	AGCTTCTCCACAGCCACAAT
GAPDH	CAGCCTCAAGATCATCAGCA	GTCTTCTGGGTGGCAGTGAT
Human
NLRP1	TCTCAAGGGGACCTGCATAC	AGCCAGCTACAGGGAAGTGA
NLRP3	AAGGAAGTGGACTGCGAGA	AACGTTCGTCCTTCCTTCCT
NLRP6	TTCATCACCAGCGTTCTGAG	GTTGCTCCAGTTCCTTCTCG
NLRP10	GGATGAGAAGCAAGCTGACC	CTTTGCCTCTCTCCATCTGC
NLRC4	GCAAGGCTCTGACCAAGTTC	TGTCTGCTTCCTGATTGTGC
Caspase-1	CCACAATGGGCTCTGTTTTT	CATCTGGCTGCTCAAATGAA
IL-1β	GGACAAGCTGAGGAAGATGC	TCGTTATCCCATGTGTCGAA
GAPDH	CAGCCTCAAGATCATCAGCA	GTCTTCTGGGTGGCAGTGAT

GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.

Table 2 Clinical and biochemical characteristics

	Control	HFD	HFD + LPS	HFD + LPS + GW
	(n = 5)	(n = 5)	(n = 5)	(n = 6)
Food/wk (g)	20.78 ± 1.41	17.33 ± 0.82a	14.08 ± 1.28ac	13.92 ± 1.23ac
BW (g)	26.70 ± 0.69	41.04 ± 4.69a	30.98 ± 3.86c	29.87 ± 3.31c
BMI (g/cm2)	0.33 ± 0.02	0.41 ± 0.04a	0.36 ± 0.02c	0.35 ± 0.02c
Liver/BW (%)	3.50 ± 0.30	3.04 ± 0.46	2.77 ± 0.27	3.08 ± 0.94
Liver/BL (g/cm)	0.10 ± 0.01	0.13 ± 0.03	0.09 ± 0.01	0.10 ± 0.03
AST (IU/L)	52.6 ± 10.33	123.8 ± 30.54a	62.0 ± 13.71c	45.67 ± 11.11c
ALT (IU/L)	23.4 ± 4.04	136.6 ± 69.43a	49.6 ± 31.09c	20.5 ± 6.12c
TG (mg/dL)	97.8 ± 19.33	69.6 ± 21.55	65.2 ± 13.16	79.2 ± 23.82
TC (mg/dL)	86.6 ± 10.92	118.4 ± 37.16	116.0 ± 9.43	135.3 ± 34.09a

Data are presented as mean ± SD. P values are presented as:

^aP < 0.05 vs control;

^cP < 0.05 vs HFD. BW: Body weight; BMI: Body mass index; BL: Body length; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TG: Triglyceride; TC: Total cholesterol; HFD: High fat diet.